Sudeep Pharma Makes Stock Market Debut
The Indian stock market welcomes a new player today as Sudeep Pharma Limited lists its equity shares on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). The highly anticipated listing follows a tremendously successful initial public offering (IPO) that captured massive investor interest. The company's shares are set to begin trading from 10:00 AM on Friday, November 28, 2025.
Overwhelming Investor Response and Listing Price Estimate
The public offering, which was open for subscription between November 21 and November 25, witnessed an overwhelming demand. According to data from the NSE, the IPO was subscribed a staggering 93.72 times overall. The breakdown of this demand reveals robust confidence from all investor classes. Qualified Institutional Buyers (QIBs) led the charge with an exceptional subscription of 213.08 times, while Non-Institutional Investors (NIIs) bid 116.72 times the allotted portion. Retail Individual Investors (RIIs) also showed strong faith, subscribing 15.65 times.
Ahead of the listing, the grey market premium (GMP) for Sudeep Pharma IPO stands at ₹121. With the upper end of the IPO price band fixed at ₹593 per share, this translates to an estimated listing price of ₹714. This signals a potential listing gain of 20.40% for investors who secured allotments.
IPO Details and Corporate Information
Sudeep Pharma, a manufacturer of pharmaceutical ingredients, raised a total of ₹895 crore through its book-built issue. The IPO comprised two parts: a fresh issue of 16.02 lakh shares worth ₹95 crore and an offer-for-sale (OFS) of 1.35 crore shares aggregating to ₹800 crore. The price band for the offering was set between ₹563 and ₹593 per share.
The final allotments for the IPO were completed on November 26. A notice from the BSE confirms that the company's shares will be listed under the 'B' Group of Securities. The stock will also participate in the Special Pre-open Session (SPOS) before regular trading commences. The IPO was managed by ICICI Securities as the book-running lead manager, with MUFG Intime India performing the role of the registrar.
